Tillkännagivande • Jul 02
Amoéba Receives Marketing Authorization For Biofungicide AXPERA In France Amoéba has obtained marketing authorization for its biofungicide AXPERA in France. This first authorisation, granted by ANSES following the evaluation conducted by France in its capacity as rapporteur Member State for European Union, now allows the other concerned Member States concerned to proceed with and finalise their national authorisation procedures in the coming weeks and months, according to each country’s specific timelines. This authorization marks the launch of the commercialization phase for AXPERA in partnership with Koppert, initially in France and then in the other European countries covered by the agreement once approvals have been granted by the relevant national authorities. AXPERA is approved by ANSES as a fungicide that acts by inhibiting the germination of fungal spores. The product is now approved for the following uses: Grapes (wine and table grapes) for Downy mildew and Powdery mildew in open field; Cucurbits for Downy mildew in open field and Powdery mildew in open field and protected conditions; Tomatoes for Late blight in open field and protected conditions and Powdery mildew in protected conditions; Eggplant for Late blight in open field and protected conditions and Powdery mildew in protected conditions; Basil for Downy mildew in open field; Lettuce (including baby leafs) for Downy mildew in open field; Artichokes for Downy mildew in open field. The product is intended for preventive use; it can be used alone, as part of a treatment program, or in combination with other fungicides approved for use against the specific disease. AXPERA is approved as a low-risk product and can be used in both conventional and organic agriculture in accordance with applicable regulations. The authorized application conditions of use contribute to the product’s appeal to farmers by combining protection, effectiveness, and ease of use. In particular, they result in the shortest re-entry period and pre-harvest interval, as well as the shortest safety distances granted by ANSES for a plant protection product. The active ingredient of AXPERA, the “Lysate of Willaertia magna C2c Maky,” is included on the list of active ingredients exempt from maximum residue limits (MRLs), offering a significant regulatory advantage: it facilitates the marketing of crops by eliminating the need for testing on treated foodstuffs. The AXPERA product is intended to be included on the French list of biocontrol products. This inclusion would offer several advantages, in particular: Meeting growing environmental and health expectations; Facilitating procedures, certifications, and specifications that promote products respectful of the environment and consumers, such as the “High Environmental Value” (Haute Valeur Environnementale) or “Zero Pesticide Residue” labels; Enhancing the product’s social acceptability and value among farmers, distributors, and industry sectors; Integrating the product into the French National Biocontrol Strategy; Getting authorization for commercial advertising. Now that the product has been approved in France - which acted as the zonal rapporteur Member State for the product’s evaluation - the other concerned Member States will be able to finalize their national approval procedures: Applications for open-field use have already been submitted in Portugal, Spain, Italy, and Greece. Applications for protected uses have already been submitted in Portugal, Spain, Italy, Greece, Belgium, Poland, and Germany. These protected uses will also be the subject of a mutual recognition application in 12 additional Member States, with a view to market access starting in 2027. This first marketing authorization in Europe, valid for a renewable 15-year period, thus serves as a major lever, facilitating future geographic expansions as well as the extension of uses, both in terms of crops and targeted diseases. Price Target Changed • Jun 09
Price target increased by 7.7% to €1.40 Up from €1.30, the current price target is provided by 1 analyst. New target price is 66% above last closing price of €0.84. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.075 next year compared to a net loss per share of €0.14 last year. Tillkännagivande • Apr 16
Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic Crops Amoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation. Price Target Changed • Apr 14
Price target decreased by 15% to €1.10 Down from €1.30, the current price target is provided by 1 analyst. New target price is 29% above last closing price of €0.86. Stock is down 12% over the past year. The company is forecast to post a net loss per share of €0.075 next year compared to a net loss per share of €0.14 last year. Tillkännagivande • Mar 26
Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,333,333
Price\Range: €0.75
Transaction Features: Subsequent Direct Listing New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€63.4m market cap, or US$73.5m). Breakeven Date Change • Sep 04
Forecast to breakeven in 2027 The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule. New Risk • Jul 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m). Price Target Changed • Jul 25
Price target decreased by 10% to €1.30 Down from €1.45, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €0.85. Stock is up 94% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.13 last year. Board Change • Jul 08
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • May 22
Amoéba S.A., Annual General Meeting, Jun 26, 2025 Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu France New Risk • Apr 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€10m). Revenue is less than US$1m (€602k revenue, or US$681k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Market cap is less than US$100m (€51.8m market cap, or US$58.7m). Price Target Changed • Apr 16
Price target increased by 57% to €1.26 Up from €0.80, the current price target is an average from 2 analysts. New target price is 29% above last closing price of €0.98. Stock is up 152% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.29 last year. New Risk • Jun 06
New major risk - Negative shareholders equity The company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m). Tillkännagivande • May 25
Amoéba S.A., Annual General Meeting, Jun 27, 2024 Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu France New Risk • Sep 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€27.0m market cap, or US$28.7m). New Risk • Sep 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€28.4m market cap, or US$30.7m). New Risk • Jul 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€31.3m market cap, or US$34.9m). Price Target Changed • Jul 12
Price target increased by 51% to €1.09 Up from €0.72, the current price target is provided by 1 analyst. New target price is 61% above last closing price of €0.68. Stock is up 29% over the past year. The company posted a net loss per share of €0.24 last year. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jul 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Is New 90 Day High Low • Feb 18
New 90-day low: €2.53 The company is down 29% from its price of €3.57 on 20 November 2020. The French market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Nov 20
New 90-day high: €3.57 The company is up 32% from its price of €2.70 on 21 August 2020. The French market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period. Is New 90 Day High Low • Sep 29
New 90-day low: €1.55 The company is down 47% from its price of €2.95 on 01 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period.